A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)

NCT04055454 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Lassa Virus Infection

Interventions

BIOLOGICAL: MV-LASV
OTHER: Placebo

Sponsor

Themis Bioscience GmbH

Collaborators

[object Object]
[object Object]
[object Object]